Enterprise Value
2.269B
Cash
520.5M
Avg Qtr Burn
-24.61M
Short % of Float
24.32%
Insider Ownership
1.35%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KT-474 (IRAK4 degrader) Details Hidradenitis suppurativa, Rheumatoid arthritis, Atopic dermatitis | Phase 2 Data readout | |
KT-294 (TYK2 Degrader) Details Inflammatory disease, Autoimmune disease | Phase 1 Data readout | |
KT-621 (STAT6 Degrader) Details Inflammatory disease, Allergy | Phase 1 Data readout | |
KT-253 Details Solid tumor/s, Cancer, Acute myeloid leukemia, Lymphoma | Phase 1 Data readout | |
KT-333 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
KT-413 Details Solid tumor/s, Cancer | Failed Discontinued |